Case Report Efficacy and Safety of RR-CHVD, a Combination of R-CHOP and RVD, as Induction Regimen Followed by BEAM-Conditioned ASCT, RVD as Consolidation and Revlimid as Maintenance for Synchronous DLBCL and MM: Towards a New Composite Therapeutic Approach
by Jean-Richard Eveillard1,*, Lanig Civi1, Loïck Nass1, Isabelle Quintin-Roué1, Vincent Rebière1,2, Jean- Christophe Ianotto1, Christophe Nicol2, Christian Berthou1, Hussam Saad1, Adrian Tempescul1
1Department of Hematology, Brest University Hospital, Brest, France
2Onco-Hematology Department, Morlaix Hospital Center, Morlaix, France
*Corresponding author: Eveillard JR, Department of Hematology, Brest University Hospital, Brest, France.
Received Date: 10 May 2025
Accepted Date: 27 May 2025
Published Date: 30 May 2025.
Citation: Eveillard JR, Civi L, Nass L, Quintin-Roué I, Rebière V, et al. (2025) Efficacy and safety of RR-CHVD, a combination of R-CHOP and RVD, as induction regimen followed by BEAM-conditioned ASCT, RVD as consolidation and Revlimid as maintenance for synchronous DLBCL and MM: towards a new composite therapeutic approach. J Oncol Res Ther 10: 10286. https://doi.org/10.29011/2574-710X.10286.
© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. Read More About Open Access Policy.